article about the career path of dr. waun ki hong
TRANSCRIPT
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
1/18
A Cancer Pioneers Personal and Professional Journey: A Korean
American Cancer Researcher Discusses His Lifes Journey and
the Passion That Spurred His Success
Waun Ki Hong, M.D. [American Cancer Society Professor]and Charles A. LeMaistre
[Distinguished Chair in Thoracic Oncology Head, Division of Cancer Medicine, Professor/
Chair]
Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson
Cancer Center
I am honored to support this ground-breaking initiative, the Korean American Cancer Control
Academy. Its also personal a joy to return to Boston, which in many ways is home to me; I
spent many years in Boston before moving to Texas. Its a wonderful opportunity to see many
old friends, especially Drs. Howard Koh and Fred Li. Id like to congratulate Dr. Moon Chenand Howard for making this conference so tremendously successful. I was also extremely
inspired by Dr. Hesung Chun Kohs lecture. Its a tough act to follow.
When I met Howard the first time in 1978, I was very impressed. He was then a senior medical
resident at Boston City Hospital, where he later served as chief medical resident. The Chief of
Medicine, Dr. Alan Cohen, first urged me to meet Howard. Now I understand why Howard
has been so successful, professionally and personally; I fully understand after hearing the
lecture from Dr. Hesung Chun Koh. Howards mom.
For this presentation, Howard asked me to give a talk from the bottom of your heart. Ive
given hundreds of scientific talks virtually everywhere in the world, but never one about myself.
This is a first for me, and it has been a very tough task. So, here is my attempt. In the following,
I will review four main periods of my life: My life in Korea before coming to this country.
My internship and residency in the United States.
My academic career, which started in 1975.
Our move to Texas in 1984, which really culminated my academic life.
Memories of Childhood in Korea
I was born in 1942, during the Japanese occupation of Korea in Word War II. Despite the
tumultuous time in the world, my early life was peaceful. I was the sixth of seven children, and
we lived in a very small town, a suburb about 30 miles from Seoul. My father, a small-business
man, wasnt very successful, but our lives seemed quite pleasant.
In 1950, when I was 7 years old, the Korean War broke out. Those years were difficult for all
of us. You can imagine how underprivileged and underserved the schools were during the war
and the early years of recovery. A decent education was almost an impossible dream.
Nonetheless, I ended up in medical school in 1961. Fortunately, I had a wonderful older brother,
Suk Ki Hong, M.D., Ph.D., a prominent Korean-born scientist and physiologist. After spending
7 years in the United States, he returned to Korea in 1960. From that time, he really involved
me in my school work. He was more than a mentor; he was like another father to me. Later on,
NIH Public AccessAuthor ManuscriptKorean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
Published in final edited form as:
Korean Korean Am Stud Bull. 2003 ; 13(1/2): 118133.
NIH-PAAu
thorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthorM
anuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
2/18
he became the chairman of the physiology department at University of Hawaii and eventually
moved to the SUNY system in Buffalo. I was deeply saddened when he passed away 2 years
ago after losing his battle with Parkinsons disease and Alzheimers. I could never thank my
brother enough for everything he did for me. I have tried to live up to his example in my
mentorship of other young physicians and researchers.
In 1967, I graduated from medical school and then served 3 years in the Korean military. In
1968, I was in Vietnam and was the flight surgeon responsible for transporting woundedsoldiers from Saigon and Vietnam to Clarke Air Base in the Phillipines and then to Daegu in
South Korea.
So, basically, I experienced three wars. I was born during World War II, grew up during the
Korean War, and served in the Vietnam War. But those years werent all bad. In 1968, God
helped me meet my wonderful wife, Mihwa, and we were married the following year. And
then the next year, there was a change in the U.S. immigration laws. I felt that America would
offer more opportunity for making the scientific advances I dreamed of, so we applied for and
were granted immigration visas.
Internship and Residency in the United States
We arrived in New York City in June 1970. My wife was eight months pregnant, and I had
$451 in my wallet. I landed as an intern in Bronx-Lebanon Hospital, a community hospital. It
was the only job I could get at the time; as a foreigner, I could not obtain a position in a teaching
hospital.
At Bronx-Lebanon, they needed slaves, not interns, i.e., people who could provide cheap labor
in the emergency room and inpatient service every other night. They needed people who would
hold clamps for hours while the surgeon operated. It was an every-other-night on-call schedule,
for 12 months, and there was no teaching. The experience was brutal. I was surprised; it was
not what I had expected when we decided to move to this country.
Furthermore, there were tremendous language and cultural barriers. I could barely speak
English. I would think that I had communicated clearly, but Americans couldnt understand
me. It was difficult to take detailed histories from patients under these circumstances.
During this time, my first son was born, on August 8, 1970. We were living in a small studio,
and this kid was wild. Becoming a parent was very difficult, although also extremely fulfilling.
Our son was a lot of fun and engaging, but when Id get home after two straight on-call shifts
thats 48 hours and try to get some rest, he was very wild.
The next challenge was to procure a residency position. I was interested in internal medicine,
but nobody wanted to write a letter of recommendation for me. So I approached one of the
orthopedic surgeons, whom I had faithfully assisted through many grueling operations by
holding clamps for 5 or 6 hours. The surgeon wrote a two-paragraph letter saying, in short,
This guy assisted my operations, and hes very strong at holding clamps. Theres no way to
obtain a residency with a letter like that!
I eventually applied to hundreds of hospitals but received few responses. With the internshipyear almost completed, I received a last-minute offer from the Boston V.A. Medical Center
after one of their trainees had dropped out. Boston! My brother advised me to accept
immediately. So, it is by accident that I ended up in Boston the first time. In retrospect, Im
sure God was helping me.
Hong and LeMaistre Page 2
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
3/18
The V.A. Medical Center in Boston presented an environment quite different from New York.
It was much more of a teaching hospital and offered more opportunities. I established some
very strong professional relationships during that time. I was particularly fortunate to have an
excellent mentor, Dr. Joel Caslowitz, who was the Assistant Chief of Medicine. I found success
there and became the chief resident. When my residency was complete, I received an absolutely
fantastic recommendation not like the previous one!
Throughout my early years of training, my time in the military, and even before that, Iestablished my own discipline. I always wanted to be independent. At that time, I still hadnt
decided on oncology as my subspecialty; I wasnt sure yet what I wanted to do. But I took care
of many cancer patients at the V. A., and I began to feel that surely there was more that could
be done for them. I became especially intrigued with improving the chances of survival and
the quality of life in people with tobacco related cancers. I believe that I was guided into
oncology through my V.A. experience, and Im very grateful that I was led into such a
rewarding career path.
Academic Medicine and a Passion for Reseach
I decided that oncology would he my field and was accepted into a very competitive fellowship
program at Memorial Sloan-Kettering Cancer Center in 1973. My second son was born during
my fellowship. I had a very good experience there in my 2 years as a medical oncology fellow,
although I didnt yet know whether I wanted to enter academic medicine or the private sector.
In some ways, my fellowship experience itself was marginal -- more accurately, I felt marginal.
When I started it, I was one of the worst fellows in the program. Despite 2 years experience
in Boston, I still had significant cultural and language problems. Many of the fellows had come
from premier residency programs at Columbia and Cornell and had more experience with
cancer patients. I was way behind; I really started at the bottom. But whats important for you
to know, especially you young folks here, is that its not important who starts first, but, rather,
who finishes first. Of the 14 members of my fellowship program, I was the first one to become
a full professor, which I accomplished at the age of 42.
Many of my cancer patients at Sloan-Kettering died. This bothered me a great deal, especially
deaths in the prime of life, like young men with testicular cancer. We didnt have drugs like
cisplatin at the time. One of my patients then was Brian Piccolo, a Chicago Bears running backand a tremendous football player, who died of testicular cancer. Another patient was Connie
Ryan, the author of The Longest Day. A smoker for many years, he died of lung cancer.
Although disturbed by what I saw, I also became intrigued with finding out what we could do
to help patients. It was an area wide-open for investigation, and the more patients I treated, the
more ideas I had. It was during that fellowship that I developed the passion for research and
academia that would fuel the remainder of my career.
I finished the fellowship in 1975, at a time when there were fewer than 600 board-certified
medical oncologists in the country. I could have easily obtained a job in the private sector,
opened up my own private practice, and made really good money. I received some very
lucrative offers. But I decided to return to Boston, even though there were no jobs around. I
applied for some jobs at Harvard I can tell some interesting stories about that and Tufts.Nothing. Fortunately, I had made some friends at the Boston V.A., and they invited me to
return as Chief of Medical Oncology. The only problem was, there were no Indians. I was both
the chief and the Indian: Chief was just a title.
Another thing that attracted me back to Boston was that I had become a die-hard Red Sox fan.
I attended many games as a resident and had remained a big fan. When I was in New York
City and the Sox played in California, Id religiously listen on the radio till 1 or 2 a.m. My wife
Hong and LeMaistre Page 3
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
4/18
thought I was crazy. When I returned to the V.A. as a faculty member, the first thing I did was
say, We have to find an apartment near Fenway Park. So we did! That was the year for the
Red Sox 1975. The Boston Red Sox went all the way to the World Series to play against
the Cincinnati Reds. Unfortunately, they lost in the seventh game. In fact, I ended up attending
the first game of the series against the Cincinnati Reds. Don Gullett pitched against Luis Tiant;
I still remember it was a 7 to 0 win over Cincinnati.
This time at the V.A., it was different. I was no longer a fellow; I had been trained at MemorialSloan-Kettering, so I had more credibility. Whenever a cancer patient was admitted, the
attending physician or the students would call me. All of a sudden, I felt responsible. Everyone
looked to me for leadership. But I had only completed a 2-year fellowship. There was no way
that I could be knowledgeable about the whole spectrum of cancer patients. At the time, there
were more than 100 cancer inpatients out of 900 beds and no other cancer specialist.
While I was at the V.A., I tried to attract students interested in cancer; in 1975, I started a
fellowship program. Im proud to say that when I left the Boston V.A. to go to Texas in 1984,
there were six faculty members covering hematology/oncology and we had produced 13 board
certified medical oncologists. This program was considered one of the strongest clinical
programs in oncology at that time in Boston. Two of the best physicians I recruited were Drs.
Dan Karp and Jim Abbruzzese from Dana Farber Cancer Center. I later recruited them to join
me at M. D. Anderson, where Dr. Abbruzzese is now Chairman of the GI Medical OncologyDepartment and Dr. Karp is Deputy Head of the Division of Cancer Medicine. The Harvard
people never respected us. I was absolutely furious about that.
We were doing very good work at the V.A. My deepest wish was to improve the quality of life
for patients who had lost so much to cancer. In fact, one of my earliest accomplishments
one that still makes me proud was developing a way to treat laryngeal cancer patients without
removing the voice box. At the time, surgical removal was the standard treatment. The quality
of life for patients who have lost the ability to talk was dismal. I was fortunate to conduct some
cisplatin-based chemotherapy trials in the late 1970s, with very promising initial results. We
showed that chemotherapy and radiation could work as well as surgery without compromising
survival, and we could save the human voice box in the process. It was a very exciting finding,
but a much bigger trial was needed to confirm our results.
With the help of Dr. Gregory Wolf from Michigan, I established the V.A. Cooperative Group
for Laryngeal Cancer Study, and we successfully competed for about $4 million in grant
money. We conducted a rigorous study of over 330 randomized patients and proved our
hypothesis that using chemotherapy and radiation can be as effective as surgery without
compromising survival. This landmark study was published in theNew England Journal of
Medicine,and our findings are now considered standard treatment. We could cure cancers
while improving the quality of life.
In 1980, we developed some exciting research projects using chemo-prevention. The field was
in its infancy. The attitude was restricted to Chemotherapy first, radiotherapy, surgery
weve got to cure the cancer! Also, the concept at the time was dose-intensity to cure the
cancer, you had to deliver high doses of chemotherapy. As a junior physician, I challenged the
senior professors by saying, This patient had widespread disease, had multiple chemotherapiesbefore, so why would extremely high doses help? I used the analogy, Why dont you just
bang your head against a concrete wall and see who hurts?! It hurts your head. In beating up
patients and giving high-dose chemotherapy, patients die at tremendous cost. Obviously, the
result of the treatment is very disappointing.
Michael Sporn, who was then at the National Cancer Institute (NCI), introduced the concept
of chemoprevention in 1976. Why do we have to wait until patients develop full-blown,
Hong and LeMaistre Page 4
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
5/18
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
6/18
Pursuing Chemoprevention Research
M. D. Anderson allowed me to study chemopreventive therapies in earnest. I was able to
establish a chemoprevention program and garner significant funding support from the NCI. I
collaborated with many talented scientists here and was able to recruit more. Shortly after
coming to M. D. Anderson, I met Dr. Reuben Lotan, a retinoid biochemist who has played an
integral role in many of my studies. In 1988, I brought an outstanding physician on board when
I recruited Dr. Scott Lippman as assistant professor of medicine for the Thoracic/Head and
Neck Medical Oncology Department. He later became chairman of the CancerChemoprevention Department, serving as principal investigator for a number of translational
chemoprevention studies and as a guiding force behind much of our work. Some of the other
team members who have played critical roles in our research include Drs. Walter Hittleman,
Jin Soo Lee, Jonathan Kurie, Fadlo Khuri, Gary Clayman, Frank Fossella, Jack Lee, Helmuth
Goepfert, Margaret Spitz, and Vassiliki Papadimitrakopoulou.
With a top-notch team assembled, we developed a comprehensive, multidisciplinary
chemoprevention research program. We were doing groundbreaking translational studies,
taking laboratory findings and rapidly translating them into new clinical treatments. I focused
on head and neck cancer and, later, lung cancer.
Initially, we began on a small scale, looking further into the use of retinoids for head and neck
cancer. We established more evidence that the agent is effective in reversing oral precancerouslesions and in preventing recurrences of head and neck cancers. Our demonstration that
chemoprevention works opened the door to research into many new promising agents. This
concept was immediately embraced by the National Surgical Adjuvant Breast and Bowel
Project, which subsequently developed the tamoxifen trial and proved this chemopreventive
agent to be very effective in preventing breast cancer in high-risk groups.
Fueled by our early successes, our chemoprevention research program grew exponentially in
1991, with the award of a Program Project grant primarily supported by the NCI. We began
large-scale clinical trials of retinoids to confirm their role in preventing or delaying head and
neck cancers, along with related laboratory and translational studies.
Since I came to M. D. Anderson, my group has been awarded a total of $40 million in NCI
peer-reviewed funding. These grants have allowed us to make truly innovative-progress. Wevepublished more than 200 papers and have come to be known as the premiere chemoprevention
research program in the country. Because of these pioneering studies, I am honored to be
considered as one of the countrys first founders of clinical chemoprevention.
Eventually, I expanded my chemoprevention research into lung cancer using several different
retinoids, the COX-2-inhibitor drug Celecoxib, and the EGF-receptor drug Iressa. In laboratory
studies, weve been looking into ways to identify people who are genetically at high risk of
developing cancer, with the ultimate goal of identifying them early and proactively treating
them with the right chemopreventive agents. This is an area in which I see tremendous potential
for the future. Its truly gratifying to help establish a whole new approach to cancer, and its
exciting to look ahead and imagine a time when a simple blood test might help people avoid
getting a deadly cancer altogether.
And also recently, the NCI awarded us a new, $13.2 million Specialized Programs of Research
Excellence (SPORE) grant for head and neck cancer research. These funds will support
investigation into several different areas, including identifying people at high risk for head and
neck cancer, studying molecularly based therapies, looking at gene therapy as a
chemopreventive agent, and further examining the power of different combinations of vitamin
A compounds in preventing cancer cells from multiplying.
Hong and LeMaistre Page 6
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
7/18
Growing Professionally
As my work expanded, so did my role at M. D. Anderson. In 1988, I was appointed Chief of
Thoracic Oncology, in addition to my role as Chief of Head and Neck Medical Oncology. With
our continued success, the two sections were redesignated the Department of Thoracic/Head
and Neck Medical Oncology in 1993, and I have served as chairman of this group since then.
Im proud to say that it has become the premiere program of its type in the country, thanks in
large part to a committed team of talented physician-researchers. In 2001, I was again
promoted, to the position of Head of the Division of Cancer Medicine, with authority over 15departments and 275 of M. D. Andersons faculty members. In this role, Im working to ensure
that our division offers the countrys best programs in patient care, research, education,
training, and fellowship opportunities.
Over the course of my career, I have published close to 550 scientific publications: more than
375 papers in peer-reviewed journals, 110 invited articles, and 62 book chapters. In addition,
Ive coauthored eight books and have given almost 300 speeches, lectures, and presentations
to audiences all over the world. Most recently, I gave the presidential address at the American
Association of Cancer Researchers (AACR) 2002 annual meeting in San Francisco. This fall,
I will deliver the keynote address at the 61 st annual meeting of the Japanese Cancer Association
in Tokyo.
Im particularly proud of certain honors and awards that I have received over the years. In1988, M. D. Anderson presented me with the prestigious Charles A. LeMaistre Chair in
Thoracic Oncology, which was later upgraded to the Charles A. LeMaistre Distinguished
Chair. In 1996, I received a Clinical Research Professorship from the American Cancer Society.
This lifetime award is one of only seven in the country. For the past 10 years, Ive been listed
in The Best Doctors in Americafor my work in head, neck, and lung cancer.
One important highlight of my career was being elected to the presidency of AACR for the
year 2001. This 15,000-member organization, started in 1907, is one of the oldest, most
prestigious cancer research organizations in the world. I am very proud to be the organizations
first Asian-American president. Ive also served on its board of directors, as program committee
chairman, and in a number of other capacities. In 1993, AACR presented me with its Richard
and Hinda Rosenthal Foundation Award; in 2000, I was honored to receive the Joseph H.
Burchenal Award.
One area I have worked to expand in the AACR is its international membership, influence, and
interests. Ive chaired several important international AACR conferences, including the
AACR/ Japanese Cancer Center Association Meeting. In the fall of 2002, I chaired an
international conference, Frontiers of Cancer Prevention Research, held in Boston. In 2004,
I will also chair the 6th Joint Conference of the AACR and the Japanese Cancer Association,
which will be held in Hawaii. I have had the opportunity to organize or chair international
research conferences for a number of other organizations, in locations ranging from the United
States, Italy, Germany, Japan, the Netherlands, France, Austria, and the United Kingdom. I
helped obtain private funding to establish a yearly travel award competition that allows dozens
of promising young Asian scientists to attend the AACR annual meetings and present their
research findings.
Ive also been active in the American Society of Clinical Oncology, which presented me with
its distinguished David A. Karnofsky Award in 2000. Over the years, Ive been able to help
several notable organizations set national policies for cancer research and education. In
addition to the organizations already mentioned. Im involved with the NCI, the Food and Drug
Administrations Oncologic Drugs Advisory Committee, the Association of American
Physicians, and the American Board of Internal Medicines Subspecialty Board of Medical
Hong and LeMaistre Page 7
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
8/18
Oncology, which is responsible for certifying medical oncologists in the United States. I serve
on the scientific advisory boards of numerous national and international cancer institutes,
including the Roy Castle Lung Cancer Foundation, the Yale Cancer Center, the University of
California at San Diego, the Fox Chase Cancer Center, the Cancer Institute of New Jersey, the
San Antonio Cancer Institute, the University of Alabama, and Vanderbilt University. I am the
deputy editor of Clinical Cancer Researchand serve on the editorial boards of many other
prestigious journals, including Cancer Research, The International Journal of Radiation
Oncology, Biology and Physics, and The Journal of the National Cancer Institute.
As a strong proponent of international communication and collaboration, Ive been honored
with international recognition on several occasions, especially by my native Korea. In 1994,
the Sam-Sung Foundation in South Korea presented me with its Ho-Am Prize in Medicine and
the Korean Broadcasting System gave me its Korean Overseas Compatriots Award in Science.
My alma mater, Yon-Sci University, presented me with its Distinguished Alumni Award in
1995, an honorary D.M.Sc. and the Grand Prize in Medicine in 2000, and a Distinguished
Achievement Award in 2001. In 2001, I was also presented with the Gold Medal of Paris from
the International Congress on Anti-Cancer Treatment, and this year I was chosen one of 20
Outstanding Korean Medical Scientists by the Korean Medical Association.
Giving Back and Having a Passion
The exciting, cutting-edge research that Ive been able to pursue at M. D. Anderson has beena rare opportunity. I truly dont think that any other institution could match it. Weve earned
the trust and respect not only of peers and colleagues around the world but also of some of the
most sought-after funding organizations. Weve been very fortunate in having brought in over
$70 million in grants since Ive been in Texas. Good-quality research depends on teamwork,
and we have been lucky to have a very good team, a solid infrastructure, and strong institutional
leadership behind us. Ive had the good fortune to work with some of the most innovative and
talented people in the field.
One of the most important things you can contribute as a physician-scientist is nurturing and
training first-rate young people and preparing the next generation of researchers. Ive had the
opportunity to be involved in training more than 200 young cancer researchers, about 60 of
them from Korea. In fact, of those 60 people, about 15 now chair cancer programs or direct
cancer centers in Korea. I think they are doing a wonderful job, and Im so happy that so many
people from the Asian countries came to us, took full advantage of what we could offer, and
went home to do wonderful work.
As a foreigner, I started at the bottom of the ladder in this country and moved up. The higher
you go, the more complicated things get and the more politics there are. Somehow, though,
Ive been very successful. People ask me, How? You dont speak English as your native
language; you dont look Caucasian. What is your secret?
When I look back now at the large body of work Ive been able to produce, Im somewhat
awed and humbled. Im deeply honored to have been able to make some contributions that
change the way we think about treating cancer and that move the world just a little closer to
eliminating the disease. As a boy in Korea dreaming of coming to the land of opportunity, I
never could have imagined I would achieve so much.
Certainly, it took a lot of hard work and tenacity, but I cant take full credit for my success.
Ive been very lucky to be in the right place at the right time, working with the right people.
Ive had wonderful teams of scientists who were as committed to this quest as I was. And Ive
had a very good, very supportive family, especially my wife, Mihwa, and my two sons, Ed and
Burt. Beyond that, its important to have good faith and integrity. If you have integrity, people
Hong and LeMaistre Page 8
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
9/18
will listen to what you say and respect what youre doing. One of the most important aspects
of integrity is generosity. I try never to take anything away from anybody. Especially in
academia, theres always a question is it your idea or my idea? I really feel that its not
important whose idea it was. If you do a good job and make some important contributions,
who benefits? Patients. And thats what really matters; thats what were all here for.
Which brings me to the most important ingredient of success: passion. I know that what has
made the crucial difference in my career is the passion and deep commitment I feel for mywork. Honors and awards are nice, but there is truly nothing more gratifying than looking into
the face of a patient who may have lived because of something I did. At the end of the day,
thats what really matters.
Hong and LeMaistre Page 9
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
10/18
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
11/18
2. .
My mentor throughout my career until his death two years ago was my older brother, Suk Ki
Hong, M.D., Ph.D. (r), a prominent scientist and physiologist. This photo of the two of us was
taken in 1990.
Hong and LeMaistre Page 11
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
12/18
3. .
I became a devoted Red sox fan in my early days in Boston, and the Red Sox remain my favorite
sports team today. Here, Im watchng their spring training in Winter Haven. Florida, in 1982.
Hong and LeMaistre Page 12
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
13/18
4. .
My wife and I raised two wonderful boys, Ed and Burt, who are now grown. This is a recent
family photo. (l to r) Mihwa, Ed, Burt, me.
Hong and LeMaistre Page 13
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
14/18
5. .
Here I am visiting with John Mendelsohn, M.D., President of M.D. Anderson Cancer Center.
Hong and LeMaistre Page 14
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
15/18
6. .
I was very proud to he chosen as one of a select few of M. D. Andersons top faculty who as
part of the organizations 60th anniversary celebration in 2001were invited to attend aweekend with former President and Mrs. Bush at their summer house in Kennebunkport,
Maine.
Hong and LeMaistre Page 15
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
16/18
7. .
In 1988, I was named to M.D. Andersons prestigious Charles A. LeMaistre Chair in Thoracic
Oncology, which was later upgraded to the Charles A. Lemaistre Distinguishes Chair.
Hong and LeMaistre Page 16
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
17/18
8. .Here I am accepting an honorary D.M.Sc. degree from my alma mater Yonsei University, in
2000. The school also presented me with the Grand Prize in Medicine that year and a
Distinguished Alumni Award in 1995.
Hong and LeMaistre Page 17
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript
-
8/11/2019 Article about the career path of Dr. Waun Ki Hong
18/18
9. .
In 2001, I was fortunate to meet Queen Silvia, the Queen of Sweden, at a symposium on
molecular targets in cancer therapy. The meeting brought together representatives from the
European Organization for Research and Treatment (EORTC), the National Cancer Institute
and the American Association for Cancer Research.
Hong and LeMaistre Page 18
Korean Korean Am Stud Bull. Author manuscript; available in PMC 2007 March 7.
NIH-PAA
uthorManuscript
NIH-PAAuthorManuscript
NIH-PAAuthor
Manuscript